Quarterly report pursuant to Section 13 or 15(d)

Segment information

v2.4.0.6
Segment information
6 Months Ended
Dec. 31, 2011
Segment information

H. Segment information:

The Company has two reportable segments based on the nature of products: biotechnology and hematology. Following is financial information relating to the Company’s reportable segments (in thousands):

 

     Quarter Ended
December 31,
    Six Months Ended
December 31,
 
     2011     2010     2011     2010  

External sales

        

Biotechnology

   $ 69,808      $ 63,080      $ 142,111      $ 126,121   

Hematology

     4,854        4,628        10,147        9,532   
  

 

 

   

 

 

   

 

 

   

 

 

 

Consolidated net sales

   $ 74,662      $ 67,708      $ 152,258      $ 135,653   
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings before income taxes

        

Biotechnology

   $ 37,878      $ 37,953      $ 77,862      $ 76,413   

Hematology

     1,681        1,427        3,599        3,349   
  

 

 

   

 

 

   

 

 

   

 

 

 

Segment earnings before income taxes

     39,559        39,380        81,461        79,762   

Unallocated corporate expenses and equity method investee losses

     (1,686     (1,707     (3,088     (3,136
  

 

 

   

 

 

   

 

 

   

 

 

 

Consolidated earnings before income taxes

   $ 37,873      $ 37,673      $ 78,373      $ 76,626